Health
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease – PRNewswire
/PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical…
LEXINGTON, Mass., March 24, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients with mild-to-moderate AD. Participants were evaluated for safety and tolerability, as well as cognitive function and markers of AD pathology. Professor Huntington Potter, together with Jonathan Woodcock, Timothy…
-
Noosa News12 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Business13 hours agoSolid superannuation gains continue to roll in
-
General11 hours agoSingapore’s world-first sustainable flights tax will see some Australians pay more to travel
-
Noosa News12 hours agoBoy charged over E-Bike crash